Meta-analytic evidence from Zhou et al. and De Hollanda Morais et al. corroborates these results, indicating that GLP-1 receptor agonists improve monthly regularity, increase the probability of ovulation, elevate SHBG levels, and decrease free testosterone, while markedly lowering BMI and central obesity [37,43]. Here, GLP1R is linked to Abdominal obesity.